SRC and chronic myelogenous leukemia, BCR-ABL1 positive: It has a broad target spectrum, including KIT, platelet-derived growth factor receptor (PDGFR), and SRC family kinases, and affects imatinib-resistant chronic myeloid leukemias 3.